Investigational drug · Phase 2
BNT164b1
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Tuberculosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BNT164b1"
First trial start
2023
Jul 31, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BNT164b1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tuberculosis
Approved drugs for the same conditions: Tuberculosis · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "BNT164b1" as an intervention, largest first.
- Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated VolunteersPivotal-lookingActive, not recruiting
BioNTech SEIndustry
NCT05547464 · 497 participants · Start Jul 31, 2023 · Primary completion Mar 12, 2026
Drug: BNT164a1; BNT164b1 · For: Tuberculosis
Sites: Manhiça, Mozambique; Maputo, Mozambique; Berea, South Africa · 8 sites in all
- Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy VolunteersPivotal-lookingCompleted
BioNTech SEIndustry
NCT05537038 · 120 participants · Start Apr 18, 2023 · Primary completion Jun 6, 2025
Drug: BNT164a1; BNT164b1 · For: Tuberculosis
Sites: Berlin, Germany; Mannheim, Germany · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.
Agrawal N, Ates LS, Schille SA, et al. · Nat Immunol 2026
Also in development for Tuberculosis
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- MTBVACBBV169Phase 32 trials
Biofabri, S.L · Tuberculosis, Tuberculosis (TB)
- TB-PPDPurified Protein Derivative of TuberculinPhase 32 trials
Chengdu CoenBiotech Co., Ltd · Tuberculosis, Latent Tuberculosis Infection
- DelamanidPhase 22 trials
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
- BNT164a1Phase 21 trial
BioNTech SE · Tuberculosis
- BTZ-043Phase 21 trial
GSK · Tuberculosis
- GSK3036656Phase 21 trial
GSK · Tuberculosis
- JDB0131Phase 21 trial
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.